DB:D05

Stock Analysis Report

Executive Summary

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Share Price & News

How has Deciphera Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: D05's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.7%

D05

-1.7%

DE Biotechs

-1.0%

DE Market


1 Year Return

145.4%

D05

-7.0%

DE Biotechs

9.1%

DE Market

Return vs Industry: D05 exceeded the German Biotechs industry which returned -7% over the past year.

Return vs Market: D05 exceeded the German Market which returned 9.1% over the past year.


Shareholder returns

D05IndustryMarket
7 Day5.7%-1.7%-1.0%
30 Day47.3%-4.1%4.4%
90 Day32.1%-10.0%13.0%
1 Year145.4%145.4%-6.7%-7.0%12.5%9.1%
3 Yearn/a51.2%49.1%24.8%13.8%
5 Yearn/a-2.4%-5.5%39.1%20.2%

Price Volatility Vs. Market

How volatile is Deciphera Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Deciphera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: D05 (€44.2) is trading above our estimate of fair value (€24.33)

Significantly Below Fair Value: D05 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: D05 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: D05 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate D05's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: D05 is overvalued based on its PB Ratio (4x) compared to the DE Biotechs industry average (3x).


Next Steps

Future Growth

How is Deciphera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

24.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: D05 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: D05 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: D05 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: D05's revenue (73.7% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: D05's revenue (73.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: D05 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Deciphera Pharmaceuticals performed over the past 5 years?

-54.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if D05 has high quality earnings.

Growing Profit Margin: Insufficient data to determine if D05's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: D05 is unprofitable, and losses have increased over the past 5 years at a rate of -54.1% per year.

Accelerating Growth: Unable to compare D05's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: D05 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: D05 has a negative Return on Equity (-25.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Deciphera Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: D05's short term assets ($642.3M) exceeds its short term liabilities ($42.3M)

Long Term Liabilities: D05's short term assets (642.3M) exceeds its long term liabilities (1.8M)


Debt to Equity History and Analysis

Debt Level: D05's debt to equity ratio (0.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if D05's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: D05 has a low level of unsold assets or inventory.

Debt Coverage by Assets: D05's debt is covered by short term assets (assets are 556.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: D05 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: D05 has sufficient cash runway for 2.903155 years if free cash flow continues to reduce at historical rates of -64.2% each year.


Next Steps

Dividend

What is Deciphera Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate D05's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate D05's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if D05's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if D05's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of D05's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Deciphera Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Steve Hoerter (48yo)

0.7yrs

Tenure

US$447,296

Compensation

Mr. Steven L. Hoerter, also known as Steve, serves as President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since March 18, 2019. He serves as Director at Constellation Pharmaceuticals,  ...


Management Age and Tenure

1.2yrs

Average Tenure

55yo

Average Age

Experienced Management: D05's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Age and Tenure

4.4yrs

Average Tenure

61yo

Average Age

Experienced Board: D05's board of directors are considered experienced (4.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$6,043,78426 Aug 19
New Leaf Venture Partners, L.L.C.
EntityCompany
Shares182,383
Max PriceUS$33.49
SellUS$11,488,61719 Aug 19
New Leaf Venture Partners, L.L.C.
EntityCompany
Shares350,000
Max PriceUS$33.36

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.


Management Team

  • Tucker Kelly (48yo)

    Executive VP

    • Tenure: 4.8yrs
    • Compensation: US$2.31m
  • Daniel Flynn (64yo)

    Executive VP

    • Tenure: 16.8yrs
    • Compensation: US$1.09m
  • Matt Sherman (63yo)

    Executive VP & Chief Medical Officer

    • Tenure: 0.08yrs
  • Chris Morl (60yo)

    Chief Business Officer

    • Tenure: 3.1yrs
    • Compensation: US$1.22m
  • Steve Hoerter (48yo)

    President

    • Tenure: 0.7yrs
    • Compensation: US$447.30k
  • Dan Martin (44yo)

    Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$3.72m
  • Peter Lasky

    Vice President of Human Resources

    • Tenure: 0.7yrs
  • Jeff Held

    General Counsel

    • Tenure: 0.7yrs
  • Stephen Ruddy (55yo)

    Chief Technical Officer

    • Tenure: 1.5yrs
  • Jen Robinson

    Vice President of Investor Relations

    • Tenure: 0yrs

Board Members

  • John Martin (58yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$256.40k
  • Mike Ross (70yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$260.15k
  • Edward Benz (73yo)

    Independent Director

    • Tenure: 3.1yrs
    • Compensation: US$260.15k
  • Patty Allen (57yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$267.65k
  • Jean-Yves Blay (57yo)

    Member of Scientific Advisory Board

    • Tenure: 4.4yrs
  • Jim Bristol (72yo)

    Chairman

    • Tenure: 4.8yrs
    • Compensation: US$296.40k
  • Mike Taylor (64yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: US$5.24m
  • Steve Hoerter (48yo)

    President

    • Tenure: 0.7yrs
    • Compensation: US$447.30k
  • Filip Janku

    Member of Scientific Advisory Board

    • Tenure: 4.4yrs
  • Steve Hodi

    Member of Scientific Advisory Board

    • Tenure: 4.4yrs

Company Information

Deciphera Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Deciphera Pharmaceuticals, Inc.
  • Ticker: D05
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.487b
  • Listing Market Cap: US$2.258b
  • Shares outstanding: 51.04m
  • Website: https://www.deciphera.com

Number of Employees


Location

  • Deciphera Pharmaceuticals, Inc.
  • 500 Totten Pond Road
  • 6th Floor
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DCPHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2017
D05DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2017

Biography

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/14 22:09
End of Day Share Price2019/11/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.